CA2908148A1 - Composes d'indoline comme inhibiteurs de granzyme b - Google Patents

Composes d'indoline comme inhibiteurs de granzyme b

Info

Publication number
CA2908148A1
CA2908148A1 CA2908148A CA2908148A CA2908148A1 CA 2908148 A1 CA2908148 A1 CA 2908148A1 CA 2908148 A CA2908148 A CA 2908148A CA 2908148 A CA2908148 A CA 2908148A CA 2908148 A1 CA2908148 A1 CA 2908148A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
carboxylic acid
compound
expected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2908148A
Other languages
English (en)
Inventor
Dale R. Cameron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIDA THERAPEUTICS Inc
Original Assignee
VIDA THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIDA THERAPEUTICS Inc filed Critical VIDA THERAPEUTICS Inc
Publication of CA2908148A1 publication Critical patent/CA2908148A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés d'indoline inhibiteurs de granzyme B, des compositions qui comprennent ces composés et des procédés d'inhibition de granzyme B chez un sujet ou de traitement d'une maladie, d'un trouble ou d'un état de santé pouvant être traité par l'inhibition de la granzyme B à l'aide desdits composés. Les composés d'indoline de l'invention présentent une solubilité avantageuse dans l'eau et inhibent efficacement la granzyme B.
CA2908148A 2013-03-29 2014-03-28 Composes d'indoline comme inhibiteurs de granzyme b Abandoned CA2908148A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361806767P 2013-03-29 2013-03-29
US61/806,767 2013-03-29
US201461941358P 2014-02-18 2014-02-18
US61/941,358 2014-02-18
PCT/CA2014/050317 WO2014153666A1 (fr) 2013-03-29 2014-03-28 Composés d'indoline comme inhibiteurs de granzyme b

Publications (1)

Publication Number Publication Date
CA2908148A1 true CA2908148A1 (fr) 2014-10-02

Family

ID=51622320

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2908148A Abandoned CA2908148A1 (fr) 2013-03-29 2014-03-28 Composes d'indoline comme inhibiteurs de granzyme b
CA2908315A Abandoned CA2908315A1 (fr) 2013-03-29 2014-03-28 Utilisations et procedes cosmetiques pour des compositions d'inhibiteur d'indoline granzyme b

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2908315A Abandoned CA2908315A1 (fr) 2013-03-29 2014-03-28 Utilisations et procedes cosmetiques pour des compositions d'inhibiteur d'indoline granzyme b

Country Status (3)

Country Link
AU (1) AU2015238789B2 (fr)
CA (2) CA2908148A1 (fr)
WO (2) WO2014153667A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605021B2 (en) 2013-03-29 2017-03-28 Vida Therapeutics Inc. Indoline compounds as granzyme B inhibitors
EP3186271A4 (fr) * 2014-08-01 2018-03-14 Vida Therapeutics, Inc. Composés d'indoline en tant qu'inhibiteurs du granzyme b
CA2994326A1 (fr) * 2014-08-01 2016-02-04 Vida Therapeutics, Inc. Composes d'uree cyclique en tant qu'inhibiteurs du granzyme b
US9458192B1 (en) 2014-08-01 2016-10-04 Vida Therapeutics Inc. Covalent granzyme B inhibitors
US9458193B1 (en) 2014-08-01 2016-10-04 Vida Therapeutics Inc. Proline compounds as Granzyme B inhibitors
US9458138B1 (en) 2014-08-01 2016-10-04 viDATherapeutics Inc. Pyrrole compounds as granzyme B inhibitors
US20190038602A1 (en) * 2016-02-03 2019-02-07 Vida Therapeutics, Inc. Granzyme b inhibitor formulations and methods for the treatment of burns
WO2018005926A1 (fr) * 2016-07-01 2018-01-04 The General Hospital Corporation Imagerie et thérapie dirigées du granzyme b
EP4074317A1 (fr) 2021-04-14 2022-10-19 Bayer AG Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050057A1 (fr) * 1999-02-22 2000-08-31 Bernstein Eric F Compositions et procedes de prevention du photovieillissement
US7326692B2 (en) * 2001-11-14 2008-02-05 The University Of Chicago Induction of immunity using inhibitors of granzymes
EP1474093A4 (fr) * 2002-02-04 2005-02-16 Merck & Co Inc Inhibiteurs de granzyme b
NZ571858A (en) * 2006-03-09 2013-08-30 Univ British Columbia Methods of treating, reducing and inhibiting the appearance of ageing in the skin
US20140056964A1 (en) * 2010-12-06 2014-02-27 The University Of British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing

Also Published As

Publication number Publication date
CA2908315A1 (fr) 2014-10-02
AU2015238789A1 (en) 2015-10-29
AU2015238789B2 (en) 2017-03-02
WO2014153666A1 (fr) 2014-10-02
WO2014153667A1 (fr) 2014-10-02

Similar Documents

Publication Publication Date Title
CA2908148A1 (fr) Composes d'indoline comme inhibiteurs de granzyme b
US10329324B2 (en) Indoline compounds as granzyme B inhibitors
JP6964096B2 (ja) ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類
KR101999195B1 (ko) 혈장 칼리크레인의 저해제로서의 벤질아민 유도체
EP1981877B1 (fr) Composes de n-hydroxyacrylamide
US9969772B2 (en) Covalent granzyme B inhibitors
CA3024120A1 (fr) Peptidomimetiques pour le traitement d'une infection a norovirus
US9969770B2 (en) Proline compounds as Granzyme B inhibitors
US9849112B2 (en) Pyrrole compounds as Granzyme B inhibitors
KR20120110091A (ko) Ｈｃｖ 프로테아제 저해제
EP3186270B1 (fr) Composés d'urée cyclique en tant qu'inhibiteurs du granzyme b
AU2021319847A1 (en) Low molecular weight protein degraders and their applications
US20200062803A1 (en) Azaindoline compounds as granzyme b inhibitors
TW200840570A (en) N-hydroxyacrylamide compounds
CN102020698B (zh) 丙型肝炎病毒蛋白酶抑制剂
WO2007144129A2 (fr) Composés organiques

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190321

FZDE Discontinued

Effective date: 20220712

FZDE Discontinued

Effective date: 20220712